- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 865314, 1 page
Cytotoxic T Lymphocytes and Vaccine Development 2013
1Department of Animal and Avian Sciences, University of Maryland, College Park, MD 20742, USA
2Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA
3Department of Veterinary Microbiology and Immunology, College of Veterinary Medicine, China Agricultural University, Beijing 100083, China
4Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA
Received 1 January 2013; Accepted 1 January 2013
Copyright © 2013 Zhengguo Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
CTLs play a critical role in fighting chronic virus infection and cancers. Despite the tremendous efforts spent so far, generating potent and highly effective CTLs remain a major roadblock for disease control (prevention and therapies). Activation of CTLs requires different stimuli and is influenced by different disease conditions. In this special issue, several papers investigated functions of cytokines, such as IL-15 and IL-6, in activation of CTLs. Several papers are focusing on the therapeutic effects of CTLs in different cancers using novel approaches targeting tumor-specific CTLs. In addition, potential markers and mechanisms for rapid progression of AIDS are suggested using SIV model.
In the first paper entitled “IL-6 production by dendritic cells is dispensable for memory T-cell generation,” Daudelin et al. describe a new observation that IL-6 is not required in APC vaccination.
In the second paper entitled “What is recent in pancreatic cancer immunotherapy?” Niccolai et al. summarize the current immunotherapy of pancreatic cancer targeting cancer-associated antigens.
In the third paper entitled “MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge,” Roulois et al. review current knowledge regarding MUC1 as a potential target tumor therapeutic vaccines.
In the fourth paper entitled “Characterization of T cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL),” Benteyn et al. report that functional TAA-specific T cells are detected in both the skin and the peripheral blood after TriMixDC-MEL therapy.
In the fifth paper entitled “CpG and interleukin-15 synergize to enhance IFN-production by activated T cells,” Cobb et al. present evidence that IL-15 synergizes with CpG in the induction of IFN-γ in activated T cells, expanding our understanding about the function of IL-15.
In the sixth paper entitled “Increased Toll-like receptor signaling pathways characterize cells in rapidly progressive SIV infection,” Marcondes et al. suggest that TLR overexpression may indicate ineffective T-cell response in rapid progression in HIV infection.
We thank all of the authors for their great contributions to this special issue and appreciate their patience in processing their manuscripts. We also want to thank all of the reviewers who went through the manuscripts multiple times, providing insightful suggestions. We really hope this special issue will continue to thrive as a timely communication platform for basic and translational research on CTLs.